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Overview: Cryptococcosis is worldwide the 
most common systemic fungal disease in cats; 
it is caused by the Cryptococcus neoformans–
Cryptococcus gattii species complex, which
includes eight genotypes and some subtypes
(strains) with varying geographical distribution,
pathogenicity and antimicrobial susceptibility. 
Cats acquire the infection from a contaminated
environment. The prognosis is favourable in most
cases, provided a diagnosis is obtained sufficiently
early and prolonged treatment is maintained.
Infection: Basidiospores are the infectious
propagules of Cryptococcus species as they
penetrate the respiratory system and induce
primary infection. Asymptomatic colonisation of 
the respiratory tract is more common than clinical
disease. Avian guanos, particularly pigeon
droppings, offer favourable conditions for the
reproduction of C neoformans. Both Cryptococcus
species are associated with decaying vegetation.
Disease signs: Cryptococcosis caused by 
C neoformans or C gattii is indistinguishable clinically.
The disease can present in nasal, central nervous
system (which can derive from the nasal form or
occur independently), cutaneous and systemic forms. 
Diagnosis: An easy and reliable test for
cryptococcosis diagnosis is antigen detection in body
fluids. Only isolation and polymerase chain reaction
allow identification of the species genotype.
Disease management: Amphotericin B,
ketoconazole, fluconazole and itraconazole have 
all been used to treat cats. Surgical excision of any
nodules in the skin, nasal or oral mucosa assists
recovery. Continued treatment is recommended
until the antigen test is negative.
Prevention: Efficient preventive measures have 
not been demonstrated. Vaccines are not available.
Agent properties
Feline cryptococcosis, discovered over a century ago, is a non-
contagious systemic fungal disease acquired from a contaminated
environment. For this reason it is not considered a zoonotic disease;
animals may serve as sentinel hosts. 
Feline cryptococcosis is caused by basidiomycetous yeasts of the
genus Cryptococcus belonging to the C neoformans–C gattii complex. A
previous classification distinguished five serotypes (A, B, C, D, AD)
according to antigenic characteristics of the capsular polysaccharide.1
The updated nomenclature based also on genotyping differentiates
two main species affecting cats: C neoformans – including the varieties













(strains) with varying geographical distribution, pathogenicity and
antimicrobial susceptibility.2
Small-size infectious propagules such as basidio spores (<2 μm) and
desiccated yeast cells (<3 μm) are easily dispersed by air flow and can
penetrate the respiratory system where the primary infection takes
place. The fungus can differentiate into several morphological forms
including yeast, chlamydospores, pseudohyphae and hyphae under
certain conditions, but it is typically present in the yeast form in mam-
malian hosts, reproducing by mitosis in animal tissues.3,4
Other species that have been rarely reported are C albidus, which
may affect immunocompromised cats, and C magnus isolated in cats
affected by otitis.5,6
European Advisory Board on Cat Diseases
The European Advisory Board on Cat Diseases (ABCD) is a body
of experts in immunology, vaccinology and clinical feline medicine
that issues guidelines on prevention and management of feline
infectious diseases in Europe, for the benefit of the health and
welfare of cats. The guidelines are based on current scientific
knowledge of the diseases and available vaccines concerned.
The latest version of the crytococcosis 
in cats guidelines is available at www.abcd-vets.org
*The ABCD is grateful to Professor Lluís Ferrer, of the Foster
Hospital for Small Animals, Cummings School of Veterinary
Medicine, Tufts University, USA, who, though not a member
of the Board, contributed to this article.
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Epidemiology
Cryptococcosis affects humans, cats, dogs, 
ferrets, horses, goats, sheep, cattle, dolphins,
birds, koalas and other marsupials.1 It has a
worldwide distribution and is observed more
commonly in cats than in dogs.7
Unfortunately, Cryptococcus is not usually
identified to the species and molecular level
with routine diagnostic sampling, and data
regarding the feline disease in Europe are
from single case reports or small case series,
since the disease usually occurs sporadically.8
Larger retrospective studies are available from
Canada, Australia and California.7,9–13
The disease is usually rare or sporadic.
However, in 1999, a large-scale outbreak of
cryptococcosis caused by C gattii for the first
time involved humans, terrestrial (dogs, cats,
ferrets, llamas, horses, birds) and marine 
(porpoises Phocoenoides dalli) animals; it
occurred on southern Vancouver Island,
British Columbia, Canada in a region charac-
terised by wet, mild winters and dry, warm
summers. It is now well known that C gattii has
a worldwide distribution with a high preva-
lence along the Pacific coast of North America.
In Europe, it has been reported from Austria,
Denmark, France, Germany, Greece, Italy, the
Netherlands, Portugal, Spain, Sweden and the
United Kingdom.2 C n var grubii also has a
worldwide distribution and is commonly 
isolated from affected individuals in various
animal species. C neoformans is considered a
cosmopolitan opportunistic pathogen in
human urban populations, whereas C gattii is a
true pathogen, more prevalent in rural areas.1
Environmental exposure and asymptomatic
colonisation of the respiratory tract are more
common than the clinical disease.14,15
Asymptomatic carriage of C gattii has been
recognised in 4.3% of cats, 1.1% of dogs and in
2% of wild animals (squirrels) trapped in
British Columbia.10,16
C neoformans ecology is usually related to the
presence of avian guanos, particularly pigeon
droppings, which offer favourable conditions
for the mitotic amplification and reproduction
of the fungus, but both Cryptococcus species
have been associated with decaying vegetation
such as eucalyptus leaves.17 Pigeons serve as 
C neoformans carriers, which likely contributes
to the worldwide distribution, as they carry
Cryptococcus species on their beaks, feathers
and legs.18 Animals, plants, soil and water-
ways are the sources from where the potential
pathogen may be contracted. 
Cats are five to six times more likely to be
affected by the disease than dogs, and three
times more than horses.7 Retrospective studies
of feline cases tended to show a preponder-
ance in males, although this finding was not
confirmed in other studies.7,13,19–23 Pedigree
breeds such as Ragdoll, Birman, Siamese and
Himalayan were considered more often affect-
ed than non-pedigree domestic cats but, again,
this finding has not been confirmed in more
recent studies.7,12,13,20,24 In contrast with other
animal species, where usually young adults
contract the infection, cats of all ages may be
affected.7,20 No seasonal trend in the diagnosis
of infection has been observed.7 Also lifestyle
does not seem to be a risk factor – the disease
has been reported in indoor cats, too.
Pathogenesis
Cryptococcus is primarily an airborne
pathogen, and the nasal cavity is usually the
primary site of infection in cats and dogs. In
most cases there is only a subclinical colonisa-
tion without the invasion of the epithelium.10
When invasion of mucosal tissues occurs, 
disease develops locally and/or systemically.
In both people and cats, the infection may fol-
low ingestion of desiccated yeast cells or, more
rarely, cutaneous inoculation of fungal forms.
The incubation period varies from months to
years, and the source of infection often
remains unknown. The virulence (genotype)
and burden of the inhaled organisms influence
the outcome of infection. From the upper res-
piratory tract the infection may spread locally
to the central nervous system (CNS) through
the ethmoid bone, and rarely also to the lower
respiratory tract or systemically.25
There are temperature-sensitive strains
which are unable to grow at temperatures
>37.0°C and may cause infections only at
body sites where the temperature is lower
(skin, nose, scrotum).26,27
Immunity
Antibodies produced against capsular antigens
are not protective. Persistent infections can
occur because the capsule of cryptococcal yeast
forms inhibits phagocytosis, and other virulence
factors such as melanin production protect the
yeast cells from oxidative damage. The organ-
ism is, therefore, able to survive inside phago-
cytic cells such as macrophages and neutrophils
and can be disseminated with these cells.2,24,28
Some studies have suggested that crypto-
coccosis has a higher prevalence or a less
favourable outcome in feline leukaemia virus-
or feline immunodeficiency virus-infected
cats,19,21 but this conclusion has not been
shared by others.12,13,20,29,30 The disease has
been reported in cats undergoing chemother-
apy or with a concurrent opportunistic infec-
tion; hence, a role for immunocompetence
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Clinical signs 
Cryptococcosis caused by C
neoformans or C gattii is clini-
cally indistinguishable.
This disease can present in
several different clinical forms,
including the nasal form, CNS
form (which can derive from
the nasal form or occur inde-
pendently), the cutaneous
form and the systemic form.
Geographical differences in
the prevalence of some clinical
presentations are postulated as being a conse-
quence of the distribution of genotypes with
different virulence. Abnormalities in blood
tests are non-specific, if pres-
ent, showing an inflammatory
process.
Nasal form
The nasal form is the most
common in cats, presenting as
a chronic sinonasal disease,
either alone or together with
local spread to the skin, sub-
cutis, bones and regional
(submandibular) lymph
nodes.7,12,20 It induces naso-
facial swelling followed by
deep non-healing ulceration
draining gelatinous exudate, chronic nasal 
discharge (monolateral or bilateral) with
serous, mucopurulent or bloody aspect, stertor
and inspiratory dyspnoea, sneezing and 
snuffling and submandibular lymphadenopa-
thy (Figures 1–3). Anorexia and subsequent
weight loss may also be a result of anosmia
affecting cats with chronic nasal disease.
Cryptococcus is an important differential in cats
with chronic nasal discharge, regardless of
whether or not facial swelling and/or skin
ulceration is present.
In some cases, a fleshy mass may protrude
from one or both nostrils. Nasopharyngeal
granulomas (resembling polyps or cancer) 
presenting with stertor, inspiratory dyspnoea
and open-mouth breathing have also been
described.32 Proliferative or ulcerated lesions
in the oral cavity or pharynx may additionally
develop. Otitis media/interna with vestibular
signs may occur.33,34 Lower respiratory tract
disease may follow and may manifest radio-
logically as only pulmonary or mediastinal
nodules.
CNS form
CNS involvement most likely arises following
local dissemination through the cribriform
plate; in such cases, sudden blindness due to
optical neuritis appears, together with seizure
or behavioural changes. In other cases dissem-
ination probably occurs haematogenously
and induces granulomatous encephalo -
myelitis with solitary or multiple lesions.13,35
Many cats show head or spinal pain; other
signs of meningeal involvement (hyperaesthe-
sia, nuchal rigidity) are not common.13
Cutaneous form
Cutaneous forms are characterised by solitary
or multiple dermal to subcutaneous nodules
in the skin: the former are suggestive of direct
inoculation, the latter of haematogenous
spread from the primary site of infection.1 The
nodules are usually non-pruritic and not
painful, and commonly accompanied by
regional lymphadenopathy.
Systemic form
Systemic forms may occur through
haematogenous dissemination and manifest
with signs of meningoencephalomyelitis 
(see CNS form), uveitis, chorioretinitis,




(Figures 4 and 5).
Apathy and cachexia
appear in cats with
severe dissemination
during the prolonged
chronic course of the
disease. The systemic
form arising from dis-
semination may or





and mild nasal deformity.
Courtesy of Maria Grazia
Pennisi
Figure 2 Cryptococcal disease: severe nasofacial swelling
and deformity. Courtesy of Maria Grazia Pennisi
Figure 3 Cryptococcal
disease: ulcerated skin
nodules on the face.
Courtesy of Maria Grazia
Pennisi
Cryptococcosis caused by C neoformans




anterior chamber. Courtesy of
Maria Grazia Pennisi
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Antigen detection
Antigen detection in blood is the test of choice,
if available, because it is fast, reliable and min-
imally invasive. Cryptococcal capsular antigen
may be detected by latex cryptococcal antigen
agglutination test (LCAT) on serum, CSF or
urine. The sensitivity and specificity of the test
is improved by pre-treating samples with heat
and a proteinase (pronase, often included in
commercial diagnostic kits) and is considered
good in cats [EBM grade III].1 In some cases,
false-negative results may occur [EBM grade
IV].35 If the antigen test is negative, and cryp-
tococcosis is still a possibility, tissue samples
should be submitted for cytology, histology
and culture. In case of titres <200 a confirmato-
ry cytology, culture or PCR is suggested.
LCAT titre is also an efficient way of moni-
toring the efficacy of therapy. Treatment is
usually continued until a negative LCAT is
obtained, but it has been reported that the titre
continues to decrease after stopping therapy
in cats with clinical resolution but still
remains positive [EBM grade III].29 
Cytology
Cytology can be an easy tool to diagnose cryp-
tococcosis because the appearance of the
organisms is characteristic and the number of
yeasts in the lesions is usually high; however,
a negative result does not exclude the diagno-
sis. Appropriate cytological samples can be
obtained using impression smears from 
ulcerated skin lesions, fine needle aspirates of
nodules, impression smears of biopsy samples
or bronchoalveolar lavage fluid or CSF taps.
In the case of renal involvement yeast may be
seen in the urinary sediment.37
Smears stained with Romanowsky-type
stain (Wright, Diff Quick, Giemsa) may show
pink to violet, round or budding extracellular
yeasts that vary in size (4–15 μm) and shape
and are typically surrounded by a more or 
less clear, thick halo corresponding to the
unstained capsule (Figures 6 and 7). If Gram
stain is used, the organism appears Gram-
Diagnosis
An easy and reliable test for cryptococcosis
diagnosis is antigen detection in body fluids.
Alternatively, samples can be collected from
lesions and submitted for cytology, culture,
histopathology and polymerase chain reaction
(PCR). These include: pleural or peritoneal
effusions; cerebrospinal fluid (CSF); speci-
mens collected from bronchoalveolar lavage;
fine needle aspirates from nodules or enlarged
lymph nodes; or biopsies taken from any
affected tissues.
An increased risk of cerebellar herniation
after CSF collection is suspected and this inva-
sive procedure should be considered only
when a CNS disease compatible with feline
cryptococcosis is not confirmed using other
suitable biological samples [EBM grade III].13
Isolation and PCR give the opportunity to





poorly defined nodules with
blurred margins in the lungs

















Figure 6 Diff Quick stained
smear of nasal exudate from




budding (arrow). Courtesy of
Richard Malik, University of
Sydney Veterinary School,
Australia
Figure 7 Diff Quick stained smear of fine needle aspirate of a
cryptococcal lesion. Note the enormous capsule surrounding
the yeast cells. Courtesy of Mark Krockenberger
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positive with a Gram-negative (pink) capsule.
A pyogranulomatous inflammatory pattern is
usually seen. Although filamentous forms are
not commonly observed in tissues, these atyp-
ical morphological forms of C neoformans may
be present in cats.26,27
Histology
Biopsy samples of nasal mucosa, lymph nodes
or skin nodules may be obtained for histology,
but they may also provide impression smears
for cytology and material for culture and PCR.
Haematoxylin-eosin stained sections show
eosinophilic bodies surrounded by a clear
halo and a pyogranulomatous reaction
(Figure 8). Mayer’s mucicarmine method
specifically stains the capsule of Cryptococcus.
Immunohistochemistry on tissue sections is
used for species differentiation, using mono-
clonal antibodies (Figure 9).38
Culture
Culture should be performed if the antigen
test is negative, when titres are low or absent.
Only samples from nasal biopsies should be
submitted for culture, because the presence of
Cryptococcus in nasal discharge cultures is not
considered evidence of disease. Positive 
culture of biopsy samples and histological
changes consistent with infection are consid-
ered diagnostic and may be used to test the
sensitivity towards antifungal drugs.
Culture of biopsy samples is more sensitive
than cytology in confirming infection [EBM
grade III]. Cryptococcus is easily isolated in
Sabouraud dextrose agar after incubation at
25°C and 37°C for 10 days but also on bacteri-
al standard media. It is now possible to differ-
entiate C neoformans from C gattii by a specific
agar test.2
When samples are contaminated by bac -
teria, as occurs in nasal secretions, media 
containing antibiotics are useful.1
PCR
PCR has been developed for genetic identifi-
cation in CSF, urine, serum and biopsy sam-
ples, but is not used routinely in practice.39–41
Antibody detection
Antibody detection is not a diagnostic tool
because it cannot distinguish subclinical infec-
tion from disease.
Diagnostic imaging
Advanced diagnostic imaging techniques (CT
and MRI) are frequently used in the eval -
uation of chronic nasal and CNS signs.
Abnormal findings in feline cryptococcosis
are the presence of chronic rhinitis, frontal
sinusitis and/or intranasal or intracranial
focal solitary or multifocal masses or fluid-
filled lesions [EBM grade III].13 Confirmation
of diagnosis is not possible by imaging alone,
but resolution of a mass lesion can be 
followed up by MRI in cats under medical
therapy.42,43 MRI findings may also include
meningeal enhancement, and optic nerve and
cribriform plate involvement.13
Prognosis
The prognosis is favourable in most cases, 
provided the diagnosis is obtained sufficiently
early (before dissemination or before the devel-
opment of irreversible lesions) and patients
and owners comply with a long course of treat-
ment (months) and follow-up (years).
Although information on outcomes is quite
limited, it seems that cats have a more
favourable prognosis than dogs or horses,
which more frequently develop lower respira-
tory, disseminated and neurological disease
with associated higher mortality [EBM grade
III].7,11,13,29
In one retrospective study, disease severity
did not influence outcome, although the pres-
ence of CNS involvement had a significantly
adverse impact on the outcome of therapy
[EBM grade III].29 By contrast, alteration of the
mental status was the only negative prognos-
tic factor in a retrospective study on cats with
the CNS form of cryptococcosis, and complete
recovery was also documented in cats with a
CNS form [EBM grade III].13,43
Figure 8 Early invasion of 
C gattii into the respiratory
epithelium of a koala. 
Note the eosinophilic body
surrounded by a clear halo.
Courtesy of Mark
Krockenberger
Figure 9 Use of
immunohistology to
demonstrate C gattii in









show up as brown
precipitates, highlighting
both the yeast cell body and






for grading the level
of evidence of
various statements
within this article is
described on 
page 533 of this
Special Issue.
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Treatment
No prospective controlled studies exist on the
treatment of feline cryptococcosis and all data
are based on retrospective studies and case
reports. Treatment guidelines have not been
established and the choice of appropriate anti-
fungal drug depends on many factors. Owner
compliance is crucial, because of the high
costs in terms of both money and time com-
mitment required for treatment.
Some retrospective studies on treatment
outcomes in feline cryptococcosis have been
reported, using a variety of criteria for evalu-
ating the success of therapy.21,44,45 In the
largest retrospective study performed on 59
cats, 68% had a successful outcome [EBM
grade III].29 Most of them needed one single
course of therapy of several months (1–24)
duration and few cats received a second
course of therapy because of clinical recur-
rence or raised LCAT titre. According to a
more recent retrospective study, the clinical
outcome may be favourable in approximately
two-thirds of treated cats [EBM grade III].7
Most recovered cats were presented with
sinonasal or single skin, subcutis or intestinal
lesions, and the ones that did not recover had
CNS or disseminated disease.
Amphotericin B, ketoconazole, fluconazole
and itraconazole have all been used to treat
cats. With regard to the effect of different ther-
apeutic protocols, there was no significant dif-
ference in outcome between cats treated with
amphotericin B-containing protocols and
those treated with azole monotherapy using
fluconazole or itraconazole [EBM grade III].29
The median cumulative dose of ampho-
tericin B for cats cured at the first attempt was
16 mg/kg (range 7–23 mg/kg). This was high-
er than the previously recommended cumula-
tive dose of 4–8 mg/kg. The median duration
of treatment for fluconazole-treated cats was
significantly shorter (4 months; range 1–8
months) than the median for the itraconazole
group (9 months; range 3–24 months).
Liposomal formulations of amphotericin B
may be better tolerated but are very expensive
and not easily available. Recommendations
for treatment based on case studies are that
fluconazole or itraconazole are good choices.
In CNS or systemic cases, amphotericin B
alone or in combination with flucytosine may
be the first choice, followed by prolonged
treatment with fluconazole or itraconazole.29
Cats with pre-existing renal disease should be
treated with itraconazole or fluconazole only.
Fluconazole seems to be more effective than
itraconazole for infections involving the CNS,
eye and urinary tract, and is also better toler-
ated [EBM grade III].1,24,43 Resistance to flu-
conazole was reported with some isolates that
nevertheless were susceptible to other azoles.2
The clinical condition of cats with cerebral
cryptococcosis may worsen soon after starting
amphotericin B therapy, presumably due to 
an inflammatory response and increased
intra cranial pressure. Short-acting cortico -
steroid (dexamethasone or prednisolone sodi-
um succinate) therapy is reported to be of
immediate benefit in such cases and associat-
ed with improved chance of survival in the
short term.13,29
Surgical excision of any nodules located in
the skin, nasal or oral mucosa must be consid-
ered as a valuable aid in cats under medical
therapy [EBM grade III].46
In general, treatment is recommended until
the antigen test is negative. If the antigen test
is negative at the time of diagnosis and the
disease was confirmed by other methods, or if
the antigen test is not available, treatment
should be continued until at least 2–4 months
after resolution of clinical signs. See Table 1
for treatment options.
Prevention
Free-roaming cats in rural areas are potential-
ly more exposed to Cryptococcus, even though
urban cats can be contaminated through
pigeon guano. The presence of avian guanos,
particularly pigeon droppings, and some
decaying vegetation substrates such as euca-
lyptus leaves, may be considered a risk fac-
tor.17 A knowledge of local fungal habitats that
carry the largest risks of exposure and about
seasonal variations in the production of infec-
tious propagules would be useful to develop
preventive measures for both human and 
animal infection.
Drug/therapy Dose and duration Comments
Itraconazole 50–100 mg/cat 
q24h 
Good absorption without food. Oral solution
better than capsules. Hepatotoxicity
possible; monitor liver enzymes
periodically/monthly
Amphotericin B 0.25 mg/kg q48h IV
to a total dose of
4–16 mg/kg
Treatment of choice for CNS infection and/or
systemic disease. Significant nephrotoxicity;
monitor renal function frequently/weekly
Flucytosine 25–50 mg/kg PO
q6h
Synergistic with amphotericin B; do not use
as single treatment
Fluconazole 50 mg/cat q12h Suggested treatment of choice, especially 
for CNS infection. Good absorption without
food. Monitor liver enzymes
Terbinafine 10 mg/kg q24h Use if resistance to azoles
Surgical 
excision
Skin, oropharyngeal and nostril granulomas
iv = intravenous, PO = oral, CNS = central nervous system
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< Cryptococcosis is worldwide the most common systemic fungal disease in cats caused
by the C neoformans–C gattii species complex.
< Cryptococcosis is a non-contagious rare or sporadic disease acquired by cats, 
usually by inhalation of organisms from a contaminated environment.
< Cryptococcosis is not considered a zoonosis; animals may serve as sentinels for
exposure of human beings.
< The disease can present in several clinical forms, including the nasal form, CNS form
(which can either derive from the nasal form or occur independently), cutaneous form
and systemic form.
< Diagnosis can be confirmed using a rapid agglutination antigen test on serum or 
body fluids.
< The prognosis is favourable, if the diagnosis is obtained early and owners cooperate
with a long course of treatment (months) and follow-up (years).
< Surgical excision of nodules located in the skin, nasal or oral mucosa is valuable
adjunctive treatment for cats undergoing antibiotic therapy.
< Antifungal treatment choices include amphotericin B, ketoconazole, fluconazole or
itraconazole, based on individual assessment. 
< Avian guano, particularly pigeon droppings, and decaying vegetation substrates 
such as eucalyptus leaves are risk factors.
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